Drug intelligence / Profile preview

miR-21-3p agomiR

Development stage: Unknown
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Local Injection, Intraperitoneal Injection

Overview

**miR-21-3p agomiR** is a chemically-modified double-strand miRNA mimic designed to mimic endogenous miR-21-3p. It is used for functional studies of miR-21-3p and has been shown to enhance fibroblast proliferation, inhibit apoptosis, and accelerate wound healing by targeting SPRY1[1][4][7]. It is also involved in regulating inflammation, mitophagy, and macrophage polarization in heart conditions[2]. Additionally, it plays a role in modulating tuberculosis infection and has implications in ferroptosis[3][5].

Other names: Chemically-modified double-strand miRNA mimics

Targets

SPRY1 (Sprouty homolog 1)Thioredoxin reductase 1 mRNA 3' untranslated regionCPT1A (Carnitine palmitoyltransferase 1A)

Beyond the preview

Go deeper on miR-21-3p agomiR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-21-3p agomiR.

Explore the full profile